CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Laurus Labs receives EIR from USFDA for API facilities
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Subscribe To Our Newsletter & Stay Updated
